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Purpose: Prostate cancer foci have a characteristic feature in magnetic resonance imag-
ing (MRI). We aimed to assess the clinical value of MRI before prostate biopsy in prostate 
cancer detection.
Materials and Methods: From March 2009 to June 2010, 154 patients were enrolled 
in this study. A total of 51 patients with a clinical suspicion of prostate cancer underwent 
prostate MRI by a 3T scanner before transrectal ultrasound (TRUS)-guided biopsies. 
A total of 103 patients with a clinical suspicion of prostate cancer underwent prostate 
MRI after biopsies. The sensitivity, specificity, and positive predictive value (PPV) were 
evaluated. In addition, tumor location of pathologic findings and ADC mapping on MRI 
were matched and compared.
Results:  The sensitivity of MRI before and after biopsy was 84.8% and 92.4%, 
respectively. The PPV of MRI before and after biopsy was 75.7% and 92.4%, respectively. 
The MRI location match percentage before and after biopsy was 89.3% and 94.1%, 
respectively.
Conclusions: Compared with other previous reports, our results show that the prostate 
cancer detection sensitivity of MRI is on the rise. Furthermore, MRI before prostate 
biopsy can provide more information by which to identify prostate cancer during pros-
tate biopsy and thus reduce the false-negative rate.
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INTRODUCTION
Prostate cancer is the third leading cause of death after 
lung cancer and colorectal cancer in Europe. The incidence 
of prostate cancer is 30 in 100,000 males [1]. According to 
the American Cancer Society, prostate cancer is the third 
leading cause of death among all cancer deaths in males, 
and in 2007, a total of 218,890 new prostate cancer patients 
were diagnosed and 27,050 patients died of prostate cancer 
[2]. As the number of prostate cancer patients  has in-
creased, the diagnosis, assessment of disease stage, and 
treatment methods have improved greatly.
　Transrectal prostate biopsy is a useful method for pros-
tate cancer diagnosis and lesion site assessment [3]. 
However, the procedure entails discomfort and has risks 
for hemorrhage and prostatitis afterwards. In addition, if 
the cancer lesions are small, biopsy may not be performed 
accurately [4-6].
　Magnetic resonance imaging (MRI) is a useful tool for 
prostate cancer diagnosis and disease staging workup. 
Particularly, at present, it is widely used to assess the loca-
tion and border of tumors as well as to determine the level 
of infiltration to adjacent tissues. Nevertheless, if MRI is 
performed after transrectal prostate biopsy, due to hemor-
rhaging within tissues, it may be difficult to assess the loca-
tion of cancer lesions and to determine the range and border 
of the tumor; consequently, the size of the lesion may be un-
derestimated or overestimated [7-9]. However, in the past 
20 years, with the introduction of diffusion-weighted imag-
ing, dynamic contrast-enhanced MRI, and MR spectro-
scopy, prostate cancer can be diagnosed more accurately 
and effectively [10-17].
　In the present study, we examined whether MRI that 
was performed before prostate biopsy is of help in the diag-Korean J Urol 2011;52:572-577
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TABLE 1. Basic patient characteristics
Group 1 (n=51) Group 2 (n=103)
Age
PSA (ng/ml)
Prostate
  volume (ml)
No. of biopsy 
  core
67.16±6.38 (56-90)
14.16±17.66 (1.02-38.9)
42.98±22.70 (13.8-77.3)
10.24±0.65 (10-12)
60.09±7.55 (50-82)
16.60±23.07 (1.27-52.4)
37.28±16.28 (14.5-68.3)
10.08±0.38 (10-12)
nosis of prostate cancer.
MATERIALS AND METHODS
From March 2009 to June 2010, the study was conducted 
on 154 patients who underwent prostate biopsy and MRI. 
Among the 154 patients, 51 patients underwent MRI be-
fore prostate biopsy (group 1) and 103 patients underwent 
MRI after prostate biopsy (group 2).
　In all patients, digital rectal examination (DRE), serum 
prostate-specific antigen (PSA) measurement, transrectal 
prostate ultrasonography (TRUS), and MRI were per-
formed at our outpatient clinic. DRE and TRUS examina-
tion were performed by a single experienced urologist.
1. Prostate biopsy protocol
Before the biopsy procedure, oral quinolone agents were 
administered to all patients to prevent infection caused by 
the procedures. All patients assumed the left down lateral 
decubitus position with their knees brought up toward 
their chest, and a transrectal ultrasound probe was in-
serted through the anus. The prostate was examined by 7 
MHz ultrasound. The peripheral zone mid-gray image of 
the prostate was optimized. Axial assessment from the 
base to the apex and sagittal planes assessment were done. 
Prostate biopsy was performed by using a standard 
spring-loaded biopsy device. According to the extended 10 
to 12 core biopsy, it was performed on the bilateral base, 
midgland, and apex of the peripheral zone. If hypoechoic 
lesions were detected within an echo view, biopsy samples 
were obtained. In addition, targeted biopsies were per-
formed in the abnormal regions of the MRI. Biopsy samples 
were labeled according to their location and were immedi-
ately stored.
2. Prostate MRI protocol
For prostate MRI, the 3-Tesla MR image system (A Tim 
System MAGNETOM Verio; SIEMENS, Germany) was 
used. No enema, drug administration, or other pretreat-
ments were performed except that the patients fasted for 
8 hours before MRI. The images were assessed by two radi-
ologists with more than 15 years of experience. They dis-
cussed the radiologic findings with each other and con-
firmed the report after discussion. The four sequences eval-
uated in this study were axial T1WI, T2WI, DWI, and ADC 
map. Imaging parameters for the axial T1-weighted fast 
spin-echo (FSE) images were repetition/echo time (TR/TE) 
600/13 ms, echo train length (ETL) 3, number of excitations 
(average) 3, matrix size 320x224, plain resolution 0.7x0.5 
mm, slice thickness 3 mm (Voxel size: 0.7x0.5x3), and ac-
quisition time 3 min 23 seconds. Axial T2-weighted FSE 
images were TR/TE 3,060/102 ms, ETL 21, number of ex-
citations (average) 3, matrix size 324x320, plain resolution 
0.7x0.5 mm, slice thickness 3 mm (Voxel size: 0.7x0.5x3), 
and acquisition time 2 min 33 seconds. Axial diffusion- 
weighted images (DWI) were TR/TE 7,300/98 ms, average 
6, ETL(-), matrix size 106x77, plain resolution 1.8x1.4mm, 
slice thickness 3 mm (Voxel size: 1.8x1.4x3), and acquis-
ition time 5 min 29 s, with free breath. DWI was obtained 
by using diffusion gradients with three b values (0, 500, and 
800 s/mm
2) along the orthogonal three directions of the mo-
tion-probing gradients. The ADC map was automatically 
created from the DWIs acquired at b factors of 500 and 800 
s/mm
2. The sensitivity encoding (GRAPPA) reduction fac-
tor was two. The slice thickness was 3 mm for all sequences 
(Sag T2 BLADE; 4 mm). The interslice gap was 0 mm in all 
sequences. The field of view was 18x18 cm for sagittal se-
quences and 15x15 cm for axial sequences.
3. Pathological specimens
After fixing the prostatectomy specimens in formalin, the 
whole prostate glands were serially blocked into approx-
imately 4 to 6 mm thick (5 mm average) sections from the 
apex to the base in the transverse planes. These specimens 
were then submitted in entirety for paraffin embedding as 
whole mounts. The average number of blocks of a radical 
prostatectomy specimen was 36.3 (range, 30-43) per case. 
After paraffin embedding, micro-sections were placed on 
glass slides and stained with hematoxylin-eosin. For all 
cases, the same pathologist assessed both the biopsy sam-
ples and the radical prostatectomy specimens, while also 
evaluating any correlations between them. For an in-
dividual cancer focus, the pathological evaluation included 
the cancer location, Gleason score, histologic type, tumor 
size, extracapsular involvement, seminal vesicle invasion, 
lymphatic/vascular invasion, lymph node metastasis, peri-
neural/prostatic urethral invasion, and surgical margin 
involvement. When multiple cancer foci were present in 
one case, several large lesions were chosen for the patho-
logical evaluation.
4. Image analysis and statistical analysis
The specimen was prepared as serial blocks and examined 
histologically in the department of pathology. Two patholo-
gists clearly marked the site where prostate cancer was lo-
cated, and the result of the prostate biopsy and MRI find-
ings of the site were compared. 
Statistical analysis was carried out by using sensitivity, 
specificity, and positive predictive value.
RESULTS
The total number of patients was 154. Of these, 51 patients Korean J Urol 2011;52:572-577
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FIG. 1. Study design and schematic 
flow of group 1.
FIG. 2. Study design and schematic 
flow of group 2.
underwent MRI before biopsy (group 1), and 103 patients 
underwent MRI after biopsy (group 2).
　The mean age of group 1 was 67.16±6.38 years, the mean 
PSA value was 14.16±17.66 ng/ml, the mean prostate size 
was 42.98±22.70 ml, and the mean number of prostate bi-
opsy cores was 10.24±0.65. The mean age of group 2 was 
69.09±7.55 years, the mean PSA value was 16.60±23.07 
ng/ml, the mean prostate size was 37.28±16.28 ml, and the 
mean number of prostate biopsy cores was 10.08±0.38 
(Table 1).
　In group 1, 36 patients were diagnosed as having pros-
tate cancer by prostate biopsy, and the remaining 15 pa-
tients were diagnosed as having benign prostatic 
hyperplasia. Of 37 patients who were diagnosed as having 
prostate cancer by MRI, 31 patients were definitely diag-
nosed as having prostate cancer by prostate biopsy. The re-
maining patients were found to have benign prostatic hy-
perplasia or chronic inflammation. Of 31 patients who were 
definitely diagnosed as having prostate cancer, the site of 
the MRI lesion matched in 28 patients. Of 14 patients who 
were diagnosed as having a low possibility of prostate can-
cer by MRI, 5 patients were diagnosed as having prostate 
cancer and the remaining 9 patients were diagnosed as 
having benign prostatic hyperplasia or chronic in-
flammation by biopsy (Fig. 1).
　In group 2, 93 patients were diagnosed as having pros-
tate cancer by prostate biopsy, and the remaining 10 pa-
tients were diagnosed as having benign prostatic hyper-
plasia. Of 93 patients who were diagnosed as having pros-
tate cancer by MRI, 86 patients were definitely diagnosed 
as having prostate cancer by prostate biopsy. The remain-
ing 7 patients were found to have benign prostatic hyper-
plasia or chronic inflammation. Of 86 patients who were 
definitely diagnosed as having prostate cancer, the site of 
the MRI lesion matched in 81 patients. Of 10 patients who 
were diagnosed as having a low possibility of prostate can-
cer by MRI, 7 patients were diagnosed as having prostate 
cancer and the remaining 3 patients were diagnosed as 
having benign prostatic hyperplasia or chronic in-
flammation by biopsy (Fig. 2).
　Cases in which the location of the primary lesions match-
ed were limited to the cases whose ADC map and the loca-
tion confirmed by the pathologic results were identical 
(Fig. 3).Korean J Urol 2011;52:572-577
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FIG. 3. (A) A 74-year-old male with prostate cancer. The PSA 
level was 7.3 ng/ml, GS was 7. The radical prostatectomy speci-
men showed one clear cancer foci. (B) The MRI images show a 
focal, round, low signal intensity area in the left peripheral zone.
　In group 1, the sensitivity for prostate cancer detection 
was 84.8%, the positive predictive value was 75.7%, and the 
matching rate of the prostate cancer location was 89.3%. 
In group 2, the sensitivity for prostate cancer detection was 
92.4%, the positive predictive value was 92.4%, and the 
matching rate of the prostate cancer location was 94.1%.
DISCUSSION
Recently, PSA screening tests have been widely performed 
for the early diagnosis of prostate cancer. As a result, for 
patients with an elevated PSA value, patients who require 
additional examinations such as TRUS and prostate biop-
sy are on the rise. Consequently, early prostate cancer with 
small lesions and early stage disease is being abundantly 
detected [18,19].
　Basically, prostate cancer is diagnosed according to PSA 
values and the pathologic results of (transrectal ultra-
sonography-guided) prostate biopsy. The purpose of pros-
tate biopsy is to confirm prostate cancer lesions as well as 
to assess the location of cancer, lesion size, and grade. The 
extended 10 to 12 core biopsy that is currently performed 
at many medical institutions examines the posterior direc-
tion of the peripheral zone. It thus has been reported that 
approximately 30% of cancer lesions located in the anterior 
peripheral zone, the lateral part, the transition zone, and 
the midline preurethral anterior fibromuscular stroma 
may be overlooked [20,21]. In addition, due to the sampling 
error that may occur during the specimen collection stage, 
the assessment of the location of cancer lesions has limited 
sensitivity [5]. Diverse sensitivities of prostate cancer de-
tection by transrectal prostate biopsy have been reported, 
from approximately 50% to 75%. It has been reported that 
the sensitivity of diagnosis could be raised up to 95% by use 
of extended 10 to 12 core biopsy [22]. Although prostate bi-
opsy shows high accuracy for the detection of cancer le-
sions, a small number of patients are still diagnosed as be-
ing negative by biopsy [23].
　In such a case, when a prostate biopsy of a patient with 
an elevated PSA is negative, urologists face a dilemma 
[24,25]. Many indexes of prostate cancer applying the PSA 
value have been reported. Although such indexes show the 
risk or probability for the presence of prostate cancer, the 
lesion site cannot be assessed by the application of indexes 
[26,27]. In addition, it has been suggested that biopsy be 
performed again on such patients, and to perform biopsy 
on more sites; nonetheless, such patients experience in-
creased cost and an increased morbidity rate [28].
　MRI differs from other radiological diagnosis methods 
such as X-ray or computed tomography, because it does not 
engage ionized radiation and thus is not harmful to the 
body. The plane images can be reconstructed as 3D images, 
and contrast and resolution are superior to computed 
tomography. In addition, images can be constructed at var-
ious angles; thus, it is useful for examining intra-pelvic or-
gans such as the prostate. According to previous reports, 
the sensitivity of prostate cancer detection by MRI is ap-
proximately 55% to 65%, and the positive predictive value 
has been reported to be approximately 80% to 85%. Due to 
the development of advanced technical methods such as 
diffusion-weighted imaging, dynamic-contrast-enhanced 
MRI, and MR spectroscopy, the sensitivity is on the rise 
[5,29,30].
　In both group 1 and group 2, the sensitivity for detecting 
prostate cancer was shown to be higher than in other older 
studies. One reason for this difference may be that PSA and 
other clinical information of the patients were shared by 
the radiologists; thus, during the interpretation, the in-
formation could be used as reference data. Hence, the possi-
bility of bias may be considered. In addition, it is thought 
that the techniques applying MRI were greatly improved 
in comparison with the past, and the development of ad-
vanced equipment may be of help to raise sensitivity. This 
could be confirmed by the difference in the sensitivity for 
detecting prostate cancer between group 1 and group 2. The 
sensitivity and positive predictive value of group 1 were 
lower than those of group 2. This may be because in the 
group 2 cases, images were assessed after the pathologic 
diagnosis. In group 1, the images were assessed before the 
pathologic diagnosis.
　Transrectal prostate biopsy is a useful method for diag-
nosing prostate cancer and for assessing the location of le-
sion, and it has been considered to be the standard assess-
ment for detecting nonsurgical cancer locations [3]. Howe-
ver, the procedure is uncomfortable, and it carries a risk Korean J Urol 2011;52:572-577
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for hemorrhage and prostatitis after the procedure. 
Furthermore, if the lesion is small, biopsy may not be per-
formed accurately [4-6]. Regarding sampling errors, that 
is pointed out to be a limitation of prostate biopsy. It could 
be overcome to a certain degree by TRUS-guided biopsy; 
nonetheless, for intra-prostatic, tiny, focal prostate cancer 
lesions, it is not at a level comparable to the sensitivity of 
MRI.
　Magnetic resonance imaging is a useful method for diag-
nosing prostate cancer and for determining disease stages. 
Particularly, it has been widely used to assess the location 
and border of tumors and the depth of infiltration to ad-
jacent organs. Its sensitivity and specificity are con-
tinuously being improved [30]. However, when MRI is per-
formed after prostate biopsy, due to hemorrhages within 
tissues, it is difficult to determine the location of lesions, 
the range, and the cancer margin border, and thus the size 
of the lesion may be underestimated or overestimated [7-9]. 
But, as confirmed in our study, until now, the sensitivity 
of MRI that is performed before prostate biopsy is not great 
enough to replace prostate biopsy.
　Accuracy, low cost, reduced morbidity rate of other dis-
eases or complications, and noninvasiveness are the best 
conditions for tumor diagnosis if possible. MRI is still an 
expensive diagnostic tool. However, it provides higher res-
olution and contrast images of suspicious lesions with 3D 
reconstruction and it makes prostate biopsy more accu-
rate, thus reducing the false-negative rate and morbidity 
rate. As observed in our study, MRI performed before pros-
tate biopsy is anticipated to be of help in the diagnosis of 
prostate cancer and the determination of the area of biopsy. 
We suggest that additional studies on more patients are re-
quired in the future.
CONCLUSIONS
The sensitivity, the positive predictive value, and the le-
sion location match rate of MRI performed before prostate 
biopsy were lower than that of MRI performed after biopsy. 
Nonetheless, the possibility of the biopsy result influenc-
ing the reading of the MRI cannot be ruled out. In compar-
ison with other previous reports, our results suggest that 
the sensitivity of prostate cancer detection by MRI is on the 
rise. We thus conclude that MRI as a screening tool to diag-
nose prostate cancer has become more useful. In addition, 
MRI before prostate biopsy can provide more information 
by which to identify prostate cancer during prostate biopsy, 
which is anticipated to be of help in reducing the false-neg-
ative rate.
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